MGH Hotline 1.23.09 The MGH is a hub of scientific research and discovery, but translating these breakthroughs into commercial applications can be a challenging and sometimes confusing process.
A newly created consortium plans to change the future of vaccine research.
The Vaccine & Immunotherapy Center (VIC) at the MGH is committed to projects that accelerate vaccine and immunotherapy development, including those dedicated to finding improved treatment options for people with Type 1 diabetes, an autoimmune disease in which a person’s pancreas stops producing insulin.
The Vaccine and Immunotherapy Center at the MGH (VIC), has joined with 24 other institutions as part of the first-ever JDRF Encapsulation Consortium in the fight against type 1 diabetes.
New research indicates that using a particular laser to pre-treat the site of a flu shot may boost the body’s immune response against influenza.
Inspired by his wife's memory, Jeffrey Gelfand, MD, and his MGH colleagues set out to create a vaccine to attack tumors in patients already diagnosed with cancer.
The Vaccine and Immunotherapy Center at Massachusetts General Hospital (VIC), has joined with 24 other institutions as part of the first-ever JDRF Encapsulation Consortium in the fight against type 1 diabetes
Pretreating the site of intradermal vaccination – vaccine delivered into the skin rather than to muscles beneath the skin – with a particular wavelength of laser light may substantially improve vaccine effectiveness without the adverse effects of chemical additives currently used to boost vaccine efficacy.
A novel approach to cancer immunotherapy may provide a cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma. A protein engineered by MGH investigators to combine a molecule targeting a tumor antigen with an immune-function stimuating protein prolonged survival in animal models of both tumors.